Bilateral generalized polymicrogyria

disease
On this page

Also known as microcephaly, short stature, and polymicrogyria with seizuresMSSPPMGYSpolymicrogyria with seizures

Summary

Bilateral generalized polymicrogyria (MONDO:0013907) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • Phenotypes (HPO): 51

Clinical features

Signs & symptoms

Clinical features (HPO)

51 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO IDTermFrequency
HP:0002194Delayed gross motor developmentVery frequent (80-99%)
HP:0012736Profound global developmental delayVery frequent (80-99%)
HP:0031936Delayed ability to walkVery frequent (80-99%)
HP:0000708Atypical behaviorFrequent (30-79%)
HP:0000733Abnormal repetitive mannerismsFrequent (30-79%)
HP:0001257SpasticityFrequent (30-79%)
HP:0002197Generalized-onset seizureFrequent (30-79%)
HP:0002300MutismFrequent (30-79%)
HP:0002510Spastic tetraplegiaFrequent (30-79%)
HP:0008936Axial hypotoniaFrequent (30-79%)
HP:0010864Intellectual disability, severeFrequent (30-79%)
HP:0011968Feeding difficultiesFrequent (30-79%)
HP:0100022Abnormality of movementFrequent (30-79%)
HP:0100704Cerebral visual impairmentFrequent (30-79%)
HP:0000252MicrocephalyOccasional (5-29%)
HP:0000729Autistic behaviorOccasional (5-29%)
HP:0001256Intellectual disability, mildOccasional (5-29%)
HP:0001332DystoniaOccasional (5-29%)
HP:0001510Growth delayOccasional (5-29%)
HP:0002020Gastroesophageal refluxOccasional (5-29%)
HP:0002069Bilateral tonic-clonic seizureOccasional (5-29%)
HP:0002079Hypoplasia of the corpus callosumOccasional (5-29%)
HP:0002123Generalized myoclonic seizureOccasional (5-29%)
HP:0002133Status epilepticusOccasional (5-29%)
HP:0002187Intellectual disability, profoundOccasional (5-29%)
HP:0002342Intellectual disability, moderateOccasional (5-29%)
HP:0002360Sleep abnormalityOccasional (5-29%)
HP:0004322Short statureOccasional (5-29%)
HP:0005216Impaired masticationOccasional (5-29%)
HP:0006956Dilation of lateral ventriclesOccasional (5-29%)
HP:0007166Paroxysmal dyskinesiaOccasional (5-29%)
HP:0007204Diffuse white matter abnormalitiesOccasional (5-29%)
HP:0007359Focal-onset seizureOccasional (5-29%)
HP:0007824Total ophthalmoplegiaOccasional (5-29%)
HP:0010553Oculogyric crisisOccasional (5-29%)
HP:0010818Generalized tonic seizureOccasional (5-29%)
HP:0010819Atonic seizureOccasional (5-29%)
HP:0010821Focal emotional seizure with laughingOccasional (5-29%)
HP:0011147Typical absence seizureOccasional (5-29%)
HP:0011153Focal motor seizureOccasional (5-29%)
HP:0011344Severe global developmental delayOccasional (5-29%)
HP:0012469Infantile spasmsOccasional (5-29%)
HP:0012704Widened subarachnoid spaceOccasional (5-29%)
HP:0025097Eyelid myoclonusOccasional (5-29%)
HP:0025100Abnormal hippocampus morphologyOccasional (5-29%)
HP:0025517Hypoplastic hippocampusOccasional (5-29%)
HP:0040288Nasogastric tube feedingOccasional (5-29%)
HP:0100660DyskinesiaOccasional (5-29%)
HP:0100716Self-injurious behaviorOccasional (5-29%)
HP:0200136Oral-pharyngeal dysphagiaOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical namebilateral generalized polymicrogyria
Mondo IDMONDO:0013907
Orphanet208447
DOIDDOID:0080920
UMLSC5139324
MedGen1684616
GARD0010786
Is cancer (heuristic)no

Also known as: bilateral generalized polymicrogyria · microcephaly, short stature, and polymicrogyria with seizures · MSSP · PMGYS · polymicrogyria with seizures

Data availability: 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disordercongenital nervous system disorderpolymicrogyriabilateral polymicrogyriabilateral generalized polymicrogyria

Related subtypes (4): bilateral frontoparietal polymicrogyria, bilateral parasagittal parieto-occipital polymicrogyria, bilateral frontal polymicrogyria, bilateral perisylvian polymicrogyria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
RTTNModerateAutosomal recessivebilateral generalized polymicrogyria6

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RTTNOrphanet:468631Microcephalic cortical malformations-short stature due to RTTN deficiency

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
RTTNHGNC:18654ENSG00000176225Q86VV8Rotatingencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RTTNRotatinInvolved in the genetic cascade that governs left-right specification.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
RTTNOther/UnknownnoARM-like, ARM-type_fold, Rotatin_N

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
male germ line stem cell (sensu Vertebrata) in testis1
oocyte1
secondary oocyte1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
RTTN238ubiquitousmarkersecondary oocyte, oocyte, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
RTTN1,555

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
RTTNQ86VV877.49

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
ciliary basal body organization13370.4×0.001RTTN
centriole-centriole cohesion11296.3×0.002RTTN
centriole replication1732.7×0.002RTTN
determination of left/right symmetry1255.3×0.004RTTN

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
RTTN00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1RTTN

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
RTTN0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.